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Background. Para-aminosalicylic acid (PAS) was one of the first antibiotics to be 
used against tuberculosis (TB) and it is still one of the last remaining drugs available 
to treat extensively drug-resistant (XDR) disease. Despite being on the market for dec-
ades, the mechanism of action of PAS is not completely understood yet. Sixteen new 
compounds against Mycobacterium tuberculosis were created in the laboratory as salic-
ylate analogues (based on their chemical structures) and their antimycobacterial activ-
ity had never been tested before. The main aim of this project was to test the activity 
of these new analogues and to understand their mechanism of action (including PAS).
Methods. The compounds were tested using three different methods (spot cul-
ture, resazurin, and MGIT system). Additionally, resistant mutants were created 
against PAS and the most promising analogue; whole-genome sequencing (WGS) was 
performed to understand their mechanism of action.
Results. One compound in particular, AD25a, showed the lowest critical concen-
tration (0.04 µg/mL) among the salicylate analogues. The WGS analysis identified a 
total of 28 single nucleotide polymorphisms (SNPs) in the AD25a-resistant mutants 
and 40 SNPs in the PAS-resistant mutants (when compared with the reference strain 
H37Rv). The SNPs identified in the AD25a and PAS-resistant mutants did not overlap. 
The genes rrs, rrl and folC were mostly involved in the PAS-resistant mutants.
Conclusion. The complete difference in the mutation profiles suggests that AD25a 
has a mechanism of action different to that of PAS, despite AD25a being synthesized as 
a salicylate analogue. WGS analysis of PAS-resistant mutants has also provided some 
interesting results. In particular, all our PAS mutants showed mutations in the rrs and 
rrl genes (16S and 23S RNA genes, respectively). These mutations should affect the 
ribosomes and the overall synthesis of proteins. This highlights a new potential mech-
anism of resistance for PAS that has never been observed before.
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